

# TEOSYAL REDENSITY® [II] ALLOWS ARTISTIC INNOVATION WHEN TREATING THE EYE AREA

*In my years as a clinician I have never felt more able to successfully treat static lateral canthal wrinkles than now, through the use of TEOSYAL Redensity® [II]\*. Of note, the use of botulinum toxin type A has been effective in the treatment of a hyperkinetic orbicularis oculi in aesthetic medicine for many years now and in particular in treating dynamic canthal lines. However this treatment modality and others besides (including the use of standard HA fillers) fail to address the more chronic static lateral canthal wrinkle effectively. Such lines evolve from the loss of natural glycosaminoglycans, and deep dermal elastic fibres which are then substituted by “short” collagen fibres.*

**TEOSYAL Redensity® [II] has now become the gold standard practice for myself and colleagues in effectively addressing static lateral canthal wrinkles.** TEOSYAL Redensity® [II] has unique characteristics which include its reduced hygroscopic nature and optimized rheological properties. The secret behind its specific viscoelasticity and cohesive index can be directly attributed to its formulation of both free and cross-linked HA at a highly specific defined concentration of 15mg/mL, with the inclusion of 0.3% lidocaine to the product to aid comfort at the injection site. The unique rheological profile that is created allows TEOSYAL Redensity® [II] to tackle highly challenging and delicate areas of the face. The incorporation of a novel patented complex in TEOSYAL Redensity® [II] allows for a further advance in redensification of the skin. The combined effect of these individual elements within TEOSYAL Redensity® [II] leads to enhanced skin nutrition and deep hydration to produce a natural and effective treatment. TEOSYAL Redensity® [II] is quite simply a standalone HA filler serving as a major

innovation in the treatment of not only lateral canthal lines but also under eye circles, tear troughs, palpebromalar grooves, and malar bags. Fig.1 is representative of pre and post-treatment pictures of a middle-aged female patient that underwent the treatment of prominent lateral canthal lines with TEOSYAL Redensity® [II] at a single sitting. TEOSYAL Redensity® [II] was administered using a retrograde injection technique with a 30G ½” needle in a supraperiosteal and deep suborbicular plane that allowed for an excellent outcome that lasted for over 12 months. Post-procedure and follow-up importantly showed the filler continued to “flow” with normal facial mimetic movements lateral to the outer orbital rim. This clearly demonstrated that TEOSYAL Redensity® [II] did not deform the natural contour of the skin overlying the outer eye and was a hallmark of its distinctive viscoelastic properties.

**Figure 1.** Pre and post-treatment pictures of a middle-aged female patient following treatment with TEOSYAL Redensity® [II] to the lateral canthal wrinkle lines. Pictures provided by Prof. Haq



\* Please refer to instructions for use



*Prof. Syed Haq  
London, UK*

- Consultant Physician and Founder of Invictus Humanus Ltd.
- Key opinion leader in anti-ageing medicine.
- Past chief medical of a UK biopharmaceutical company developing a platform for the treatment of Alzheimer's disease.
- Coordinator of two MHRA registered UK phase II double blind clinical trials. Achieved an Orphan Drug Designation with the USFDA in 2014.
- Author of 100+ peer-reviewed articles/abstracts in e.g., Journal of Clinical Investigations and Nature Medicine.

## A FEW RECENTLY PUBLISHED PAPERS

K. Bong, “3Lift for nasolabial folds”, Body Language, September 2016.

W. Carey and S. Weinkle, “Retraction of the Plunger on a Syringe of Hyaluronic Acid Before Injection: Are we safe?,” Dermatologic Surg., vol. 41, no. c, pp. S340-S346, 2015.

H. Sundaram, N. Mackiewicz, E. Burton, L. Peno-Mazzarino, E. Lati, and S. Meunier, “Pilot comparative study of the topical action of a novel, crosslinked resilient hyaluronic acid on skin hydration and barrier function in a dynamic, three-dimensional human explant model,” J. drugs dermatology, vol. 15, no. 4, pp. 434-441, 2016.